NCT02879695View on ClinicalTrials.gov

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 25, 2017

Primary Completion Date

May 22, 2023

Study Completion Date

July 18, 2026

Conditions
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic LeukemiaRefractory Mixed Phenotype Acute Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

BIOLOGICAL

Blinatumomab

Given IV

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

BIOLOGICAL

Ipilimumab

Given IV

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (7)

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

40536

University of Kentucky/Markey Cancer Center, Lexington

43210

Ohio State University Comprehensive Cancer Center, Columbus

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

06520

Yale University, New Haven

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH